Synapse - Rona Yaeger

Results (329)

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

Meeting Abstract

Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer – Evaluating radiation, ablation and surgery (ERASur)

Meeting Abstract

Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
International Journal of Radiation Oncology, Biology, Physics (2023)

Fulltext@MSK | Save

KRAS(G12D) inhibition in pancreatic cancer: Fas expression facilitates immune clearance

Editorial

Yeh, C.; Park, W.; Yaeger, R.
Developmental Cell (2023)

Fulltext@MSK | Save

Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation

Journal Article

Bekaii-Saab, T. S.; Yaeger, R.; Spira, A. I.; Pelster, M. S.; Sabari, J. K.; Hafez, N.; Barve, M.; Velastegui, K.; Yan, X.; Shetty, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004

Meeting Abstract

Yaeger, R.; Shi, Q.; Dueck, A. C.; Dib, E. G.; Kazmi, S. M. A.; Alese, O. B.; Krishnamurthi, S. S.; Nixon, A. B.; Shergill, A.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations

Meeting Abstract

Beck, J. T. T.; McKean, M.; Gadgeel, S. M.; Bowles, D. W.; Haq, R.; Yaeger, R.; Taylor, M. H.; Maity, A. K.; Drescher, S.; Oliver, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Meeting Abstract

Kopetz, S.; Yoshino, T.; Kim, T. W.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T. S.; Eng, C.; Yaeger, R.; Desai, J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade

Meeting Abstract

Randon, G.; Nakamura, Y.; Yaeger, R.; Lonardi, S.; Cremolini, C.; Elez, E.; Nichetti, F.; Ghelardi, F.; Nasca, V.; Bergamo, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis